CME: Advanced prostate cancer: optimizing management strategies
Cost: FreeView Offer chevron_right
Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.
By the end of the session the participant will be able to:
- Recall the pathophysiology of aPC in a manner that informs treatment mechanisms
- Describe differences in approach between hormone-sensitive and castration-resistant aPC
- Identify the treatment modalities currently available for management of aPC and apply them to patient cases using evidence-based medicine
- Describe emerging treatment options presently available for aPC, their mechanisms of action and safety, and anticipated place in therapy